Published in Anal Chim Acta on February 10, 2006
Guidelines for the welfare and use of animals in cancer research. Br J Cancer (2010) 6.97
Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem (2007) 2.45
Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab (2007) 2.41
Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation. Br J Pharmacol (2009) 1.60
1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain. J Med Chem (2010) 1.46
1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties. J Med Chem (2007) 1.32
Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs. Eur J Pharm Sci (2010) 1.29
Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase. Bioorg Med Chem (2006) 1.23
Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am J Pathol (2009) 1.23
Development of a high-throughput screen for soluble epoxide hydrolase inhibition. Anal Biochem (2006) 1.19
Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase. Cell Biol Toxicol (2008) 1.06
Opposite regulation of cholesterol levels by the phosphatase and hydrolase domains of soluble epoxide hydrolase. J Biol Chem (2008) 1.04
Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys. Br J Pharmacol (2012) 1.02
Synthesis and structure-activity relationship of piperidine-derived non-urea soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett (2012) 0.84
The 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic pain. Drug Metab Dispos (2015) 0.81
Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties. J Med Chem (2010) 0.80
Design, synthesis and evaluation of non-urea inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett (2011) 0.80
Screening candidate anticancer drugs for brain tumor chemotherapy: pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues. Invest New Drugs (2012) 0.76
In vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors. Biochem Pharmacol (2015) 0.75
Comprehensive evaluation of formulation factors for ocular penetration of fluoroquinolones in rabbits using cassette dosing technique. Drug Des Devel Ther (2016) 0.75
Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol (2005) 3.38
Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol (2002) 2.86
Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov (2003) 2.81
Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J Med Chem (2004) 2.43
Mechanistic investigation of ionization suppression in electrospray ionization. J Am Soc Mass Spectrom (2000) 2.05
Matrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at picogram per milliliter concentrations. Anal Chem (1998) 1.90
In vitro metabolism of the mammalian soluble epoxide hydrolase inhibitor, 1-cyclohexyl-3-dodecyl-urea. Drug Metab Dispos (2003) 1.14
Determination of ketotifen and its conjugated metabolite in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. Rapid Commun Mass Spectrom (2003) 1.09
Rapid determination of soluble epoxide hydrolase inhibitors in rat hepatic microsomes by high-performance liquid chromatography with electrospray tandem mass spectrometry. Anal Biochem (2001) 0.99
Rapid determination of oral pharmacokinetics and plasma free fraction using cocktail approaches: methods and application. Pharm Res (1998) 0.93
Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: studies with cis-stilbene oxide, carbamazepine 10, 11-epoxide and naphthalene. J Pharmacol Exp Ther (1996) 0.93
Reduction of animal usage by serial bleeding of mice for pharmacokinetic studies: application of robotic sample preparation and fast liquid chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl (2001) 0.91
Combinatorial chemistry in drug discovery. Nat Biotechnol (1997) 0.90
High-performance liquid chromatographic mass spectrometric method for the determination of ursodeoxycholic acid and its glycine and taurine conjugates in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.86
The use of capillary high performance liquid chromatography with electrospray mass spectrometry for the analysis of small volume blood samples from serially bled mice to determine the pharmacokinetics of early discovery compounds. Rapid Commun Mass Spectrom (1999) 0.86
Whatever happened to cassette-dosing pharmacokinetics? Drug Discov Today (2004) 0.85
Specific, sensitive and accurate liquid chromatographic-tandem mass spectrometric method for the measurement of ribavirin in rat and monkey plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 0.85
Chemical substructures in drug discovery. Drug Discov Today (2003) 0.84
Genetically modified mouse models for pharmacogenomic research. Nat Rev Genet (2004) 0.84
The investigation and the use of high flow column-switching LC/MS/MS as a high-throughput approach for direct plasma sample analysis of single and multiple components in pharmacokinetic studies. J Pharm Biomed Anal (2002) 0.83
The simultaneous determination of mixtures of drug candidates by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry as an in vivo drug screening procedure. Rapid Commun Mass Spectrom (1997) 0.82
[Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology]. Arzneimittelforschung (2004) 0.80
Pharmacokinetic screening for the selection of new drug discovery candidates is greatly enhanced through the use of liquid chromatography-atmospheric pressure ionization tandem mass spectrometry. J Chromatogr A (1997) 0.80
A new generic column switching system for quantitation in cassette dosing using LC/MS/MS. J Pharm Biomed Anal (2003) 0.79
Mass spectrometry-based metabolomics. Mass Spectrom Rev (2006) 5.23
Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A (2005) 4.07
Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension (2002) 3.66
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov (2009) 3.46
Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol (2005) 3.38
Metabolomics: building on a century of biochemistry to guide human health. Metabolomics (2005) 3.01
Synaptic potentiation onto habenula neurons in the learned helplessness model of depression. Nature (2011) 2.98
Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res (2004) 2.98
Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res (2005) 2.95
Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol (2002) 2.86
An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension (2005) 2.76
Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol (2004) 2.59
Regulation of ceramide biosynthesis by TOR complex 2. Cell Metab (2008) 2.57
Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem (2007) 2.45
Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J Med Chem (2004) 2.43
Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab (2007) 2.41
Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol (2012) 2.40
Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res (2006) 2.33
The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS. J Lipid Res (2002) 2.32
Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies. Anal Biochem (2005) 2.26
Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci U S A (2005) 2.25
Epoxyeicosatrienoic acids regulate Trp channel dependent Ca2+ signaling and hyperpolarization in endothelial cells. Arterioscler Thromb Vasc Biol (2007) 2.17
Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chem (2009) 2.16
The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc Natl Acad Sci U S A (2003) 2.13
The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A (2005) 2.10
Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A (2006) 2.07
Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat (2006) 2.03
Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension (2005) 2.01
Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. Annu Rev Pharmacol Toxicol (2012) 2.01
The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol (2007) 1.99
Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem (2006) 1.95
Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A (2006) 1.95
Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol (2010) 1.87
In vitro biologic activities of the antimicrobials triclocarban, its analogs, and triclosan in bioassay screens: receptor-based bioassay screens. Environ Health Perspect (2008) 1.82
Occurrence of endocrine-disrupting chemicals in indoor dust. Sci Total Environ (2008) 1.81
Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett (2006) 1.77
Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol (2005) 1.76
Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids. J Lipid Res (2010) 1.76
Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest (2011) 1.74
Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet (2006) 1.74
Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci (2006) 1.71
Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways. Proc Natl Acad Sci U S A (2008) 1.69
Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem (2005) 1.69
Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A (2013) 1.66
Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol (2009) 1.64
Triclocarban enhances testosterone action: a new type of endocrine disruptor? Endocrinology (2007) 1.63
Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci U S A (2007) 1.60
Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation. Br J Pharmacol (2009) 1.60
An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol (2005) 1.59
Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis. Biochemistry (2004) 1.59
Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A (2002) 1.51
Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem Pharmacol (2009) 1.49
Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol (2003) 1.49
1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain. J Med Chem (2010) 1.46
Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci U S A (2011) 1.45
Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP. Proc Natl Acad Sci U S A (2011) 1.45
Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am J Physiol Heart Circ Physiol (2008) 1.44
Metabolic profiling of major vitamin D metabolites using Diels-Alder derivatization and ultra-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem (2008) 1.44
Lipoxin generation is related to soluble epoxide hydrolase activity in severe asthma. Am J Respir Crit Care Med (2014) 1.44
Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J Cardiovasc Pharmacol (2008) 1.42
The Photorhabdus Pir toxins are similar to a developmentally regulated insect protein but show no juvenile hormone esterase activity. FEMS Microbiol Lett (2005) 1.40
Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci U S A (2009) 1.40
Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet (2008) 1.38
Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J Pharmacol Exp Ther (2010) 1.38
Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys (2007) 1.38
PCB-induced oxidative stress in endothelial cells: modulation by nutrients. Int J Hyg Environ Health (2002) 1.36
Metabolomics--a new exciting field within the "omics" sciences. Environ Health Perspect (2004) 1.35
Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling. Hypertension (2006) 1.34
Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. Am J Physiol Heart Circ Physiol (2004) 1.34
Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin Sci (Lond) (2009) 1.34
1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties. J Med Chem (2007) 1.32
A baculovirus-encoded protein tyrosine phosphatase gene induces enhanced locomotory activity in a lepidopteran host. Proc Natl Acad Sci U S A (2005) 1.32
Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats. Hypertension (2002) 1.32
Human soluble epoxide hydrolase: structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids. Protein Sci (2005) 1.32
Investigation of human exposure to triclocarban after showering and preliminary evaluation of its biological effects. Environ Sci Technol (2011) 1.31
Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications. J Med Chem (2012) 1.30